By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Essen BioScience today said that it will provide ion channel screening services for Swiss drug firm Nycomed.

Ann Arbor, Mich.-based Essen said that the firms will collaborate on screening, optimizing, and developing modulators of voltage-gate ion channels for potential use as pain therapeutics. Essen said that it will contribute its expertise in ion channel drug discovery, planar array electrophysiology, and in vitro profiling.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.